Business
Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
Strong Xywav™ Adoption With 3,900 Active Xywav Patients Exiting The First Quarter Continued Zepzelca™ Growth Across Second-Line SCLC Setting Xywav in
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Strong Xywav™ Adoption With 3,900 Active Xywav Patients Exiting The First Quarter\n Continued Zepzelca™ Growth Across Second-Line SCLC Setting\n Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date\n On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader\n Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition\n 23% of Revenue from Recently Launched Products; Total Revenues Increased 14% to $607.6 Million Compared to First Quarter 2020\n 2021 Total Revenue Guidance Affirmed at $2.55 Billion to $2.70 Billion\n\n\nDUBLIN, May 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021.\n\"Demand for Xywav is strong, as both patients and physicians embrace the health benefits associated with reducing daily sodium intake. We also continue to see robust uptake of Zepzelca among both platinum-resistant and platinum-sensitive small cell lung cancer patients, consistent with the positive feedback we've received on its profile,\" said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. \"We are on track to deliver significant revenue growth and diversification in 2022, are poised for two additional product launches this year and look forward to completing the acquisition of GW Pharmaceuticals this month, all key milestones in our transformation to an innovative biopharmaceutical company and neuroscience leader.\"\nRobert Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer, added, \"Across our R&D organization, we've continued our track record of strong execution. We presented positive Xywav data in idiopathic hypersomnia (IH) at the American Academy of Neurology Annual Meeting. We are also pleased to have announced that FDA granted priority review of Xywav in IH with a PDUFA goal date set for August 12, 2021, bringing us another step closer to delivering this important treatment to patients with IH, for whom there is currently no FDA-approved therapy. Further, our JZP458 program remains on track with a potential approval in mid-2021. I'm proud that our continued execution en...